Clinical meaning
Controlled substances exert their effects through specific neuroreceptor systems: opioids bind mu, kappa, and delta receptors in the central nervous system modulating pain perception and reward pathways via endogenous endorphin circuits. Benzodiazepines enhance gamma-aminobutyric acid (GABA) activity at GABA-A receptors by increasing chloride channel opening frequency, producing anxiolytic, sedative, and anticonvulsant effects. Stimulants such as amphetamines and methylphenidate increase synaptic dopamine and norepinephrine concentrations by blocking reuptake transporters and, in the case of amphetamines, promoting vesicular release. Tolerance develops through receptor downregulation and desensitization, while physical dependence involves neuroadaptive changes that produce withdrawal symptoms upon abrupt discontinuation, necessitating structured tapering protocols.
Diagnosis & workup
Diagnostics & workup: - Prescription Drug Monitoring Program (PDMP) query before each controlled substance prescription - Urine drug screening (UDS) at baseline and periodically for opioid therapy - COWS (Clinical Opiate Withdrawal Scale) scoring for buprenorphine initiation - Baseline ECG for stimulants and methadone prescribing - Cardiovascular assessment (blood pressure, heart rate) before stimulant therapy - Growth charts and height/weight monitoring in pediatric stimulant patients - Screening tools: CAGE-AID, DAST-10, or ORT for substance misuse risk